Although drug-eluting stents (DESs) have radically
|
|
- Betty Sparks
- 5 years ago
- Views:
Transcription
1 CLINICAL STUDY Impact of Coronary Stent Fracture on Restenotic Neointimal Tissue Characterization After Drug-Eluting Stent Implantation An Integrated Backscatter Intravascular Ultrasound Study Yasuhiro Uchida, 1 MD, Satoshi Ichimiya, 1 MD, Hideki Ishii, 2 MD, Hideo Oishi, 1 MD, Toshijiro Aoki, 1 MD, Yusuke Miki, 1 MD, Toshiki Kawamiya, 1 MD, Hitoshi Ichimiya, 1 MD, Junji Watanabe, 1 MD, Masaaki Kanashiro, 1 MD, Shinji Hayano, 2 MD, Susumu Suzuki, 2 MD, Tetsuya Amano, 3 MD, Tatsuaki Matsubara, 4 MD and Toyoaki Murohara, 2 MD Summary Although drug-eluting stents (DESs) reduce the rates of in-stent restenosis (ISR) and subsequent target lesion revascularization, stent fracture (SF) after DES implantation has become an important concern because of its potential association with restenosis and stent thrombosis. We aimed to assess the pathogenic impact of SF on in-stent restenotic neointimal tissue components after DES implantation. We analyzed 43 consecutive patients (14 with SF and 29 without SF) with ISR requiring revascularization after DES implantation between January 2008 and March For evaluation of in-stent tissue components, integrated backscatter intravascular ultrasound (IB-IVUS) was performed. SF was defined as complete or partial separation of stent segments observed using plain fluoroscopy or intravascular ultrasound. On volumetric IB-IVUS analyses, patients with SF had a significantly higher percentage of lipid tissue volume within the neointima and a significantly lower percentage of fibrous tissue volume than those without (37.3 ± 18.9% versus 24.9 ± 12.4%, P = 0.02, and 61.2 ± 18.3 versus 72.6 ± 12.1%, P = 0.04, respectively). Moreover, SF was positively correlated with the percentage of lipid volume on multiple linear regression analysis after adjustment for confounding factors (β = 0.36, P = 0.03). The interval from stent implantation was similar in both groups (47.0 ± 28.7 versus 37.7 ± 33.3 months; P = 0.39). In conclusion, SF is associated with larger lipid tissue volume within the neointima after DES placement, suggesting a contribution to the development of neoatherosclerosis and vulnerable neointima. Thus SF might lead to future adverse coronary events. (Int Heart J 2017; 58: ) Key words: Restenosis, Neoatherosclerosis Although drug-eluting stents (DESs) have radically reduced the rates of in-stent restenosis (ISR) and subsequent target lesion revascularization compared with bare-metal stents, 1-3) widespread use of DES has given rise to several unresolved important issues. Particularly, concerns about late stent thrombosis, very late thrombosis, and late catch-up phenomenon have been raised. 3-5) Recently, several reports documented the development of neoatherosclerosis inside DES, 6-8) suggesting a potential impact on late complications after stent implantation. In particular, stent fracture (SF) after DES implantation has recently become an important problem because of its potential association with ISR, target lesion revascularization, and stent thrombosis. 9-11) However, the influence of SF on restenotic neointimal tissue characterization after DES implantation has not been fully evaluated. Integrated backscatter intravascular ultrasound (IB- IVUS) allows tissue characterization of coronary plaques, with excellent correlation with histological findings. 12) Lipid-rich plaques assessed by IB-IVUS have been associated with an increased risk of adverse coronary events, including acute coronary syndrome. 13) Accordingly, we here investigated the relationship between SF and in-stent restenotic neointimal tissue components after DES implantation using IB-IVUS. Methods Patients, study design, and definition: From January 2008 to August 2014, we prospectively recruited patients with ISR requiring percutaneous coronary intervention (PCI) after DES implantation at Yokkaichi Municipal Hospital. ISR was defined as diameter stenosis 50% within the stented segment by coronary angiography. All patients From the 1 Department of Cardiology, Yokkaichi Municipal Hospital, Yokkaichi, 2 Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, 3 Department of Cardiology, Aichi Medical University School of Medicine, Nagakute and 4 Department of Internal Medicine, School of Dentistry Aichi Gakuin University, Nagoya, Japan. Address for correspondence: Yasuhiro Uchida, MD, Department of Cardiology, Yokkaichi Municipal Hospital, Shibata, Yokkaichi, Aichi , Japan. y-uchida1122@sepia.ocn.ne.jp Received for publication November 14, Revised and accepted January 17, Released in advance online on J-STAGE November 17, doi: /ihj All rights reserved by the International Heart Journal Association. 861
2 862 Uchida, ET AL IntHeartJ November 2017 Figure 1. Study flow chart. ISR indicates in-stent restenosis; and SF, stent fracture. included in this study had objective evidence of myocardial ischemia detected by typical symptoms or noninvasive tests such as stress electrocardiography and stress myocardial scintigraphy. We excluded patients with recurrent restenosis, thrombotic lesions, and total occlusion, and inadequate lesions for intravascular ultrasound (IVUS) analysis. In total, 63 consecutive patients with 63 ISR lesions were enrolled in this study. Of these, 20 were excluded because of the above-mentioned reasons. Finally, 43 consecutive patients with 43 ISR lesions were evaluated (Figure 1). SF was defined as complete or partial separation of stent segments observed using plain fluoroscopy without contrast injection or IVUS. 14,15) SF was classified as grade I to V: I = involving a single-strut fracture; II = 2 or more strut fractures without deformation; III = 2 or more strut fractures with deformation; IV = multiple strut fractures with acquired transection but without a gap; and V = multiple strut fractures with acquired transection with a gap in the stent body. 16) Angiographic diagnosis of SF required an independent view and the agreement of 2 independent cardiologists. Diagnosis of SF by IVUS was based on a careful review of the IVUS images and the agreement of 2 independent cardiologists. Acute coronary syndrome included acute myocardial infarction and unstable angina pectoris. The former was diagnosed by an elevation in at least one positive cardiac biomarker (creatine kinase, creatine kinase-mb, or troponin), distinctive electrocardiogram changes, and continuous acute chest pain. The latter was defined as angina with progressive chest pain or angina at rest. Clinical presentation of ISR included both stable angina and unstable angina pectoris. The estimated glomerular filtration rate on admission was calculated according to a formula developed for the Japanese population: 194 age serum creatine ( for women). 17) All patients provided informed consent, and the study was approved by the hospital ethics committee. Quantitative coronary angiography, conventional IVUS, and IB-IVUS analyses: Coronary angiography and IVUS were performed prior to PCI, after intracoronary injections of isosorbide dinitrate and intravenous administration of heparin. Quantitative coronary angiography was performed with an analysis system (CAAS, Pie Medical, Maastricht, The Netherlands). The end-diastolic phase was selected for quantitative coronary angiographic analysis. Using the outer diameter of the contrast-filled guiding catheter as the reference standard, the reference vessel diameter, minimal lumen diameter, percent diameter stenosis, and lesion length were measured. Angiographic patterns of ISR were classified into focal or diffuse according to Mehran s classification, with a restenosis length of 10 mm as the cut-off between the two. 18) Conventional IVUS and IB-IVUS measurements were initially acquired using a Galaxy system (Boston Scientific, Natick, MA, USA), with a 40-MHz mechanically rotating IVUS catheter (Atlantis SR Pro; Boston Scientific), motorized catheter pullback (0.5 mm/second), and custom software (IB-IVUS, YD Company, Ltd., Nara, Japan), between January 2008 and November However, the original IB-IVUS system was then updated to the VISIWAVE system (Terumo, Tokyo, Japan), and this was used with a 40-MHz mechanically rotating IVUS catheter (ViewIT; Terumo, Tokyo, Japan), motorized catheter pullback (0.5 mm/second), and custom software (VISIATLAS; Terumo, Tokyo, Japan), between December 2010 and August Conventional IVUS measurements were performed according to the standards laid out by the American College of Cardiology and the European Society of Cardiology. 19) The transducer was advanced to the distal reference lesion, and then automated pullback was performed to the proximal reference lesion through the instent lesion. All in-stent segments were assessed at an axial interval of 1 mm. Conventional 2-dimensional IVUS image analysis was conducted for lumen cross-sectional area (CSA), stent CSA, and neointimal CSA (neointimal CSA = stent CSA lumen CSA) using the software of the IVUS system. A two-dimensional IVUS measurement was performed at the site of the minimum lumen area and SF. Conventional 3-dimensional images were obtained with reference to the sum of stent CSA, lumen CSA, and neointimal CSA at an axial interval of 1 mm for the segments analyzed, along with the stented lesion volume, lumen volume, and total neointimal volume. IB signals were acquired using a personal computer equipped with custom software connected to an IVUS imaging system to obtain radio frequency signal trigger output. US backscattered signals were generated with a 40- MHz IVUS catheter mechanically rotating at a speed of 0.5 mm/second. IB values were calculated as an average power using a fast Fourier transform (expressed in db). In accordance with previous studies, IB values were defined as follows: -29 db < IB for calcified tissue, -49 db < IB -29 db for fibrous tissue, and -49 db IB for lipid tissue. 20,21) Applying the definition of the IB value for neointimal tissue components, the neointima was similarly classified according to the IB value. 21) The percentage of calcified tissue area (calcified tissue area/neointima area), the
3 IntHeartJ November 2017 STENT FRACTURE AND IN-STENT NEOATHEROSCLEROSIS 863 Figure 2. A: Plain fluoroscopy without contrast injection, coronary angiography, and serial conventional IVUS and IB-IVUS images from patients with grade III SF (percentage of lipid volume and fibrous volume 49.5% and 49.2%, respectively). Partial stent struts separation with deformation was confirmed (arrow head). B: Plain fluoroscopy without contrast injection, coronary angiography, and serial conventional IVUS and IB- IVUS images from patients without SF (percentage of lipid volume and fibrous volume 17.4% and 80.9%, respectively). Table I. Baseline Patient Characteristics SF (n = 14) non SF (n = 29) Age 69.9 ± ± Male 10 (71%) 26 (90%) 0.28 Body mass index 22.9 ± ± Hypertension 8 (57%) 24 (83%) 0.15 Dyslipidemia 11 (79%) 18 (62%) 0.46 Diabetes mellitus 5 (36%) 19 (66%) 0.13 Current smoking 3 (21%) 6 (21%) 0.95 Estimated glomerular filtration rate 58.4 ± ± Lipid profiles, at initial PCI High-density lipoprotein cholesterol, mg/dl 57.0 ± ± Low-density lipoprotein cholesterol, mg/dl ± ± Triglyceride, mg/dl ± ± Lipid profiles, at PCI for ISR High-density lipoprotein cholesterol, mg/dl 57.3 ± ± Low-density lipoprotein cholesterol, mg/dl ± ± Triglyceride, mg/dl ± ± Stent implantation for acute coronary syndrome 6 (43%) 8 (28%) 0.51 Clinical presentation of restenosis 0.85 Stable angina 10 (71%) 23 (79%) Unstable angina 4 (29%) 6 (21%) Interval from stent implantation, months 47.0 ± ± Medications (when ISR was identified) Aspirin 14 (100) 29 (100) 1 Thienopyridine 11 (79%) 21 (72%) 0.95 ACEI/ARB 7 (50%) 20 (69%) 0.38 β-blocker 5 (36%) 9 (31%) 0.97 Statin 12 (86%) 19 (66%) 0.31 Values are mean ± SD or n (%). SF indicates stent fracture; PCI, percutaneous coronary intervention; ISR, in-stent restenosis; ACEI, angiotensin-converting enzyme inhibitor; and ARB, angiotensin receptor blocker. P percentage of fibrous tissue area (fibrous tissue area/ neointima area), and the percentage of lipid tissue area (lipid tissue area/neointima area) were automatically generated by the IB-IVUS system. The volume percentages of calcified (calcified tissue volume/neointima volume), fibrous (fibrous tissue volume/neointima volume), and lipid tissue (lipid tissue volume/neointima volume) were also acquired. Each neointimal component was calculated with the sum of calcified, fibrous, and lipid tissue areas in each CSA at 1-mm axial intervals for the segments analyzed.
4 864 Uchida, ET AL IntHeartJ November 2017 Table II. Characteristics of ISR SF (n = 14) non SF (n = 29) Location 0.34 Left anterior descending artery 7 (50%) 16 (55%) Left circumflex artery 1 (7.1%) 6 (21%) Right coronary artery 6 (43%) 7 (24%) Types of drug-eluting stents 0.07 Sirolimus-eluting stent 12 (86%) 18 (62%) Paclitaxel-eluting stent 1 (7.1%) 0 (0.0%) Everolimus-eluting stent 0 (0.0%) 7 (24%) Zotarolimus-eluting stent 1 (7.1%) 4 (14%) Stent diameter 2.95 ± ± Total stent length 37.9 ± ± Number of stents 1.7 ± ± Quantitative coronary angiography Reference vessel diameter 2.89 ± ± Minimal lumen diameter 0.78 ± ± % diameter steonsis 72.1 ± ± Lesion length 8.1 ± ± Restenosis pattern 0.85 Focal 11 (79%) 22 (76%) Diffuse 3 (21%) 9 (24%) Grade of SF Grade I 7 (50%) Grade II 3 (21%) Grade III 3 (21%) Grade IV 0 (0%) Grade V 1 (7.1%) Values are mean ± SD or n (%). SF indicates stent fracture; and ISR, instent restenosis. P Ohota et al. demonstrated grayscale IVUS and IB-IVUS data to be directly comparable between Boston Scientific s and Terumo s systems so that both are in line with the gold standard of histology for plaque constituents. 22) Representative cases are shown in Figure 2. Statistical analyses: Statistical analyses were performed with the SPSS software (Statistical Package for the Social Sciences), program version 18 (SPSS, Chicago, IL, USA). Categorical variables between SF and non-sf groups were compared with χ 2 or Fisher s exact tests and continuous variables with the Student s t-test. Simple linear regression analysis was performed to assess the relationship between percent lipid and fibrous tissue volume, and various parameters. Multiple linear regression analysis was conducted with adjustment for the interval from stent implantation, 6) and the variables with a P-value < 0.20 on simple linear regression analysis. Statistical significance was defined as a P-value < Results Baseline patient characteristics: Of the 43 patients, SF was observed in 14 (32.6%). The baseline clinical characteristics of SF and non-sf groups are summarized in Table I. There were no differences in age, sex, coronary risk factors, lipid profiles, clinical presentation of ISR, and medications when ISR was identified between the two groups. Also, the interval periods from DES implantation were similar (47.0 ± 28.7 versus 37.7 ± 33.3 months; P = 0.39). Characteristics of ISR: ISR characteristics are detailed in Table II. No significant differences were detected in lesion location, quantitative coronary angiography analysis, and restenosis patterns between the two groups. However, patients with SF tended to have undergone PCI using sirolimus-eluting stents more frequently. Besides, the SF group showed significantly longer total stent lengths and greater numbers of implanted stents than the non-sf group (37.9 ± 13.8 versus 23.9 ± 13.6 mm; P = 0.005, 1.7 ± 0.9 versus 1.2 ± 0.4; P = 0.048, respectively). In-stent restenotic tissue characterization: Table III summarizes data about cross-sectional and volumetric tissue characterization of in-stent neointima assessed by conventional IVUS and IB-IVUS. The intra- and interobserver variabilities of the percent lipid and fibrous tissue volumes were well correlated [r = 0.91 (P < 0.01) and r = 0.90 (P < 0.01), r = 0.88 (P < 0.01) and r = 0.86 (P < 0.01), respectively]. In the 2-dimentional IB-IVUS analysis, the percent lipid tissue area was significantly larger and the percent fibrous tissue area was significantly smaller in the SF group than in the non-sf group (37.2 ± 20.3% versus 23.0 ± 13.5%, P = 0.01; and 61.2 ± 19.8% versus 74.4 ± 12.7%, P = 0.02, respectively). Also, neointima at the site of SF was rich in lipid tissue in the SF group. Similarly, in the volumetric analysis, the lipid tissue volume in the SF group was significantly greater than in the non-sf group and the fibrous tissue volume was significantly less (37.3 ± 18.9% versus 24.9 ± 12.4%, P =
5 IntHeartJ November 2017 STENT FRACTURE AND IN-STENT NEOATHEROSCLEROSIS 865 Table III. In-stent Restenotic Neointimal Tissue Characterization SF (n = 14) non SF (n = 29) IB-IVUS system 0.85 GALAXY system 5 (36%) 8 (28%) VISIWAVE system 9 (64%) 21 (72%) 3-dimentional conventional IVUS Stent volume, mm ± ± Lumen volume, mm ± ± Neointimal volume, mm ± ± Neointimal volume (%) 64.1 ± ± dimentional IB-IVUS Calcified tissue volume, % 1.7 ± ± Fibrous tissue volume, % 61.2 ± ± Lipid tissue volume, % 37.3 ± ± dimentional conventional IVUS (minimum lumen area) Stent area, mm ± ± Lumen area, mm ± ± Neointimal area, mm ± ± Neointimal area, (%) 72.1 ± ± dimentional IB-IVUS (minimum lumen area) Calcified tissue area, % 1.3 ± ± Fibrous tissue area, % 61.2 ± ± Lipid tissue area, % 37.2 ± ± dimentional conventional IVUS (SF) Stent area, mm ± 1.9 Lumen area, mm ± 0.7 Neointimal area, mm ± 2.2 Neointimal area, (%) 73.6 ± dimentional IB-IVUS (SF) Calcified tissue area, % 0.8 ± 0.5 Fibrous tissue area, % 59.5 ± 19.6 Lipid tissue area, % 39.5 ± 19.7 Values are mean ± SD or n (%). SF indicates stent fracture; IB-IVUS, integrated backscatter intravascular ultrasound; and IVUS, intravascular ultrasound. P 0.02; and 61.2 ± 18.3% versus 72.6 ± 12.1%, P = 0.04, respectively). Results of simple and multiple linear regression analyses are shown in Table IV, V. On simple linear regression analysis, the presence of SF had a significant positive correlation with the percentage of lipid volume and a negative correlation with the percentage of fibrous volume within in-stent neointimal tissue (r = 0.38, P = 0.02; and r = -0.33, P = 0.04, respectively). After adjusting for confounding factors, SF was positively correlated with the percentage of lipid tissue volume and negatively correlated with the fibrous tissue volume (β = 0.36, P = 0.03; and β = -0.32, P = 0.047, respectively). Discussion The major findings of the present study are as follows: (1) after DES implantation, patients with SF had a significantly greater percent lipid volume in the restenotic neointimal tissue and a significantly lower percent fibrous volume based on conventional IVUS and IB-IUVS analyses; and (2) patients with SF had significantly longer total stent lengths and greater numbers of implanted stents during the previous PCI. The incidence of SF in the clinical setting has been reported to be about 1-8%. 14,23) Several studies have demonstrated that sirolimus-eluting stents are more likely to cause SF because of the closed-cell design and the stainless steel material with low flexibility and conformability. 24) Furthermore, it has been reported that overlap stenting and longer stent length are associated with SF. 24) Concordant with previous studies, our patients with SF had undergone PCI using longer and a greater number of stents compared with those without. Moreover, the rate of sirolimus-eluting stent use tended to be higher in the SF group. At present, we mainly use second-generation DES. Although, compared with sirolimus-eluting stents, the rates of SF after second-generation DES implantation are relatively low, SF still occurs. 10,25-27) Therefore, we must continue to pay attention to SF in case of longer or overlapping stenting for tortuous or hinged lesions. SF has been associated with higher potential risks of ISR, target lesion revascularization, and stent thrombosis. 9) Although it is not fully understood why SF causes adverse coronary events, the mechanisms are probably related to lower drug delivery at the fracture site and higher mechanical irritation by the fractured struts, causing smooth muscle cell proliferation, and impaired reendothelialization. In addition to these factors, in-stent neoatherosclerotic development might be a mechanism of
6 866 Uchida, ET AL IntHeartJ November 2017 Table IV. Simple Linear Regression Analysis Percent lipid tissue volume Percent fibrous tissue volume r P r P SF Interval from stent implantation Male Hypertension Dyslipidemia Diabetes mellitus egfr < 60 ml/minute/1.73 m Smoking Use of sirolimus-eluting stent ACEI/ARB β-blocker Statin SF indicates stent fracture; ACEI, angiotensin-converting enzyme inhibitor; and ARB, angiotensin receptor blocker. Table V. Multiple Linear Regression Analysis for Confounding Factors Percent lipid tissue volume Percent fibrous tissue volume β coefficient P β coefficient P SF Interval from stent implantation Dyslipidemia Smoking SF indicates stent fracture. late coronary events including stent thrombosis. According to a previous study, adverse pathologic findings such as stent thrombosis and restenosis at the fracture sites were really observed in SF with grade IV and V. 16) Although grades of SF were relatively low in our study, stent struts at the fracture site could give continuous stress to arterial intima and induce inflammation. Thus, SF might lead to in-stent restenotic neoatherosclerosis. A recent histopathology study by Nakazawa et al. demonstrated a higher incidence of neoatherosclerotic change linearly with time course after DES implantation. 6) The correlation between the interval from stent implantation and lipid or fibrous tissue volume in this study is not contradictory with the previous study. However, because of the small number, statistical significance was not apparent in our study. Furthermore, it should be noted that the median duration from stent implantation in their study was 361 days ( days, interquartile range), in contrast to our 848 days (322-2,148 days, interquartile range). Since longer stent implant duration has also been identified as an independent risk factor for SF, 16) this difference could clearly have influenced the results. To the best of our knowledge, this is the first report that showed the impact of SF on in-stent restenotic neointimal tissue characterization. We should be careful about the incidence of neoatherosclerosis and adverse coronary events, including ST, for patients with SF. Study limitations: This study has several limitations. First, only 43 patients were involved from a single center. For this reason, the possibility of selection bias and low statistical power must be considered. Second, we used two different kinds of conventional IVUS and IB-IVUS systems. Although this might influence the results, it has been proven that data with these two systems were essentially comparable. Third, we analyzed only the neointima requiring target lesion revascularization rather than stable neointimal tissue. Fourth, IB-IVUS was initially validated for the atherosclerosis of native coronary arteries, not for the neointima within stented segments. Further validation assessments may therefore be required. Conclusions SF is associated with a larger lipid tissue volume within the neointima after DES placement, suggesting a contribution to the development of neoatherosclerosis and vulnerable neointima. Thus, SF might lead to future adverse coronary events including restenosis, target vessel revascularization, stent thrombosis, and late catch-up phenomenon. Disclosures Conflicts of interest: The authors do not have any potential conflicts of interest associated with this study. References 1. Morice MC, Serruys PW, Sousa JE, et al; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de
7 IntHeartJ November 2017 STENT FRACTURE AND IN-STENT NEOATHEROSCLEROSIS 867 Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: Moses JW, Leon MB, Popma JJ, et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: Suzuki S, Ishii H, Matsudaira K, et al. Long-term outcome of drug-eluting vs. bare-metal stents in patients with acute myocardial infarction. Subgroup analysis of the Nagoya acute myocardial infarction study (NAMIS). Circ J 2013; 77: Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large twoinstitutional cohort study. Lancet 2007; 369: Park KW, Kim CH, Lee HY, et al. Does late catch-up exist in drug-eluting stents: insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents. Am Heart J 2010; 159: Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: Kang SJ, Mintz GS, Akasaka T, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drugeluting stent implantation. Circulation 2011; 123: Fu Q, Suzuki N, Kozuma K, et al. Quantitative optical coherence tomography analysis for late in-stent restenotic lesions. Int Heart J 2015; 56: Lee SE, Jeong MH, Kim IS, et al. Clinical outcomes and optimal treatment for stent fracture after drug-eluting stent implantation. J Cardiol 2009; 53: Umeda H, Kawai T, Misumida N, et al. Impact of sirolimuseluting stent fracture on 4-year clinical outcomes. Circ Cardiovasc Interv 2011; 4: Kubo S, Kadota K, Ozaki M, et al. Difference in clinical and angiographic characteristics of very late stent thrombosis between drug-eluting and bare-metal stent implantations. Circ J 2013; 77: Kawasaki M, Takatsu H, Noda T, et al. In vivo quantitative tissue characterization of human coronary arterial plaques by use of integrated backscatter intravascular ultrasound and comparison with angioscopic findings. Circulation 2002; 105: Sano K, Kawasaki M, Ishihara Y, et al. Assessment of vulnerable plaques causing acute coronary syndrome using integrated backscatter intravascular ultrasound. J Am Coll Cardiol 2006; 47: Umeda H, Gochi T, Iwase M, et al. Frequency, predictors and outcome of stent fracture after sirolimus-eluting stent implantation. Int J Cardiol 2009; 133: Doi H, Maehara A, Mintz GS, et al. Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture. Am J Cardiol 2009; 103: Nakazawa G, Finn AV, Vorpahl M, et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J Am Coll Cardiol 2009; 54: Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for longterm outcome. Circulation 1999; 100: Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37: (Review). 20. Okubo M, Kawasaki M, Ishihara Y, et al. Development of integrated backscatter intravascular ultrasound for tissue characterization of coronary plaques. Ultrasound Med Biol 2008; 34: Hayano S, Ishii H, Ichimiya S, et al. Renal dysfunction and atherosclerosis of the neointima following bare metal stent implantation. Am J Nephrol 2013; 38: Ohota M, Kawasaki M, Ismail TF, Hattori K, Serruys PW, Ozaki Y. A histological and clinical comparison of new and conventional integrated backscatter intravascular ultrasound (IB- IVUS). Circ J 2012; 76: Chung WS, Park CS, Seung KB, et al. The incidence and clinical impact of stent strut fractures developed after drug-eluting stent implantation. Int J Cardiol 2008; 125: Chakravarty T, White AJ, Buch M, et al. Meta-analysis of incidence, clinical characteristics and implications of stent fracture. Am J Cardiol 2010; 106: (Review). 25. Kuramitsu S, Iwabuchi M, Haraguchi T, et al. Incidence and clinical impact of stent fracture after everolimus-eluting stent implantation. Circ Cardiovasc Interv 2012; 5: Otsuka F, Vorpahl M, Nakano M, et al. Pathology of secondgeneration everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation 2014; 129: Nomura T, Suzuki N, Takamura S, Kyono H, Kozuma K. Threeyear clinical and angiographic outcomes after everolimus-eluting stent implantation in patients with a history of coronary artery bypass grafting. Int Heart J 2016; 57:
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationAnalysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent
Analysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent implantation. Department of Cardiology, Ehime Prefectural Imabari
More informationSirolimus-Eluting Stents for Treatment of In-Stent Restenosis
Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationCulprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationΑγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
More informationImpact of Metabolic Syndrome on Tissue Characteristics of Angiographically Mild to Moderate Coronary Lesions
Journal of the American College of Cardiology Vol. 49, No. 11, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.12.028
More informationJournal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009
More informationActa Cardiol Sin 2018;34: doi: /ACS _34(2) A
Original Article Acta Cardiol Sin 2018;34:124 129 doi: 10.6515/ACS.201803_34(2).20171115A Coronary Artery Disease Vascular Healing Response after Everolimus-Eluting Stent Implantation in Acute Coronary
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationAssessment of plaque morphology by OCT in patients with ACS
Assessment of plaque morphology by OCT in patients with ACS Takashi Akasaka, M.D. Department of Cardiovascular Medicine Wakayama, Japan Unstable plaque Intima Lipid core Plaque rupture and coronary events
More informationMULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION
MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides Euromedica Kyanous Stavros, Thessaloniki.
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationA Case of Recoiling of Everolimus - eluting Stent at the Ostium of the Right Coronary Artery by Out - stent Plaque Progression
Jikeikai Med J 2016 ; 63 : 71-6 Case Report A Case of Recoiling of Everolimus - eluting Stent at the Ostium of the Right Coronary Artery by Out - stent Plaque Progression Haruka Kimura, Tetsuya Ishikawa,
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationComplex PCI. Your partner in complex PCI: In-stent restenosis (ISR)
Comple PCI Your partner in comple PCI: Your partner in comple PCI: Philips provides a portfolio of specialty coronary diagnostic and therapy devices that enable safe and effective treatment of a wide variety
More informationDrug eluting stents (DES) have decreased
JACC: CARDIOVASCULAR IMAGING VOL. 5, NO. 11, 1 1 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36. PUBLISHED BY ELSEVIER INC. http://dx.doi.org/1.116/j.jcmg.1.. BRIEF REPORT OCT-Verified
More informationImpact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary
More informationVery late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography
Journal of Cardiology (2008) 52, 290 295 CASE REPORT Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography Takahiro Sawada (MD),
More informationOptical coherence tomography patterns of in-stent restenosis: Comparison between bare-metal stent and drug-eluting stent
Optical coherence tomography patterns of in-stent restenosis: Comparison between bare-metal stent and drug-eluting stent heart institute, Division of cardiology, Tokyo, Japan Yusuke Watanabe, Ryuta Asano,
More informationFFR and IVUS Guided DES Implantation in Long Diffuse Lesions
FFR and IVUS Guided DES Implantation in Long Diffuse Lesions Can We Reach Optimal DES Expansion With Conventional Stent Delivery System in Long Diffuse Lesion? Seung-Jea Tahk, MD., PhD. Ajou University
More informationIn the field of interventional cardiology, drug-eluting stent
Summary Three-Year Clinical and Angiographic Outcomes After Everolimus-Eluting Stent Implantation in Patients With a History of Coronary Artery Bypass Grafting Takahiro Nomura, 1 MD, Nobuaki Suzuki, 1
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationAnalysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography.
Analysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography. Division of Cardiology, Department of Internal Medicine, Fasculty of Medicine, Kinki University,
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationPredictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease
Original Article Acta Cardiol Sin 2009;25:1 6 Coronary Artery Disease Predictors of 6-Month Angiographic Restenosis inside Bare-Metal Stent in Chinese Patients with Coronary Artery Disease Yung-Lung Chen,
More informationCoronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy
Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Takayuki Ohno, MD, Shinichi Takamoto, MD, Noboru Motomura, MD, Minoru Ono,
More informationClinical Characteristics of In-stent Neoatherosclerosis Causing Late Stent Failure
Original Paper J Jpn Coron Assoc 2016; 22: 245-250 Clinical Characteristics of In-stent Neoatherosclerosis Causing Late Stent Failure Koji Isodono, Akiko Matsuo, Atsushi Kyodo, Yumika Tsuji, Akira Sakamoto,
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationas a Mechanism of Stent Failure
In-Stent t Neoatherosclerosis e osc e os s as a Mechanism of Stent Failure Soo-Jin Kang MD., PhD. University of Ulsan College of Medicine, Heart Institute Asan Medical Center, Seoul, Korea Disclosure I
More informationDivision of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan
Association between continuously elevated C-reactive protein and restenosis after percutaneous coronary intervention using drug-eluting stent in angina patients Division of Cardiovascular Medicine, Jichi
More informationNine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
More informationIntravascular Ultrasound
May 2008 Beth Israel Deaconess Medical Center Harvard Medical School Intravascular Ultrasound Matthew Altman, HMS III Gillian Lieberman, MD BIDMC Department of Radiology Presentation Overview 1. Patient
More informationComparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary in-stent Restenosis F. Airoldi, et al. Am J Cardiol (2006)
Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary in-stent Restenosis F. Airoldi, et al. Am J Cardiol (2006) 97;1182-7 n&list_uids=16616023 Value of the American College
More informationFor Personal Use. Copyright HMP 2014
Original Contribution Thin-Strut Drug-Eluting Stents are More Favorable for Severe Calcified Lesions After Rotational Atherectomy Than Thick-Strut Drug-Eluting Stents Yasuharu Lee, MD, Akihiro Tanaka,
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationCardiovascular Research Foundation and Columbia University Medical Center, New York.
Virtual Histology Intravascular Ultrasound Analysis of Non-culprit Attenuated Plaques Detected by Grayscale Intravascular Ultrasound in Patients with Acute Coronary Syndromes Xiaofan Wu, Akiko Maehara,
More informationDeclaration of conflict of interest. Nothing to disclose
Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han
More informationMuzina Akhtar, Wei Liu. History of ISR visualization. Introduction
Perspective Use of intravascular ultrasound vs. optical coherence tomography for mechanism and patterns of in-stent restenosis among bare metal stents and drug eluting stents Muzina Akhtar, Wei Liu Cardiology
More informationCLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus
CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus OPTICAL COHERENCE TOMOGRAPHY (OCT) IVUS and OCT IVUS OCT
More informationKey Words Angioplasty Coronary artery disease Revascularization Stent drug eluting stent
J Cardiol 26 Dec; 48 6 : 325 331 3 mm : Initial and Mid-Term Effects of 3 mm Long Sirolimus-Eluting Stents in Patients With Diffuse Long Coronary Lesions: Comparison With Bare Metal Stents Abstract Yosuke
More informationLate and Very Late Drug-Eluting Stent Malapposition Serial 2-Year Quantitative IVUS Analysis
Late and Very Late Drug-Eluting Stent Malapposition Serial 2-Year Quantitative IVUS Analysis Soo-Jin Kang, MD; Gary S. Mintz, MD; Duk-Woo Park, MD; Seung-Whan Lee, MD; Young-Hak Kim, MD; Cheol Whan Lee,
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.039
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationIntravascular ultrasound-based analysis of factors affecting minimum lumen area in coronary artery intermediate lesions
Journal of Geriatric Cardiology (2016) 13: 169 174 2016 JGC All rights reserved; www.jgc301.com Research Article Open Access Intravascular ultrasound-based analysis of factors affecting minimum lumen area
More informationOCT; Comparative Imaging Results with IVUS, VH and Angioscopy
OCT; Comparative Imaging Results with IVUS, VH and Angioscopy Takashi Akasaka, M.D. Department of Cardiovascular Medicine Wakayama, Japan Comparison among coronary imaging techniques OCT IVUS MRI CAG Angioscopy
More informationRelationship between Angiographic Late Loss and 5-Year Clinical Outcome after Drug-Eluting Stent Implantation
Original Article http://dx.doi.org/10.3349/ymj.2013.54.1.41 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 54(1):41-47, 2013 Relationship between Angiographic Late Loss and 5-Year Clinical Outcome after
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More information1830 MIYOSHI T et al. Circ J 2018; 82: ORIGINAL ARTICLE doi: /circj.CJ
1830 MIYOSHI T et al. Circ J 2018; 82: 1830 1835 ORIGINAL ARTICLE doi: 10.1253/circj.CJ-17-1396 Imaging Assessment of Second- and Third-Generation Drug-Eluting Stents on Chronic Coronary Angioscopy Multicenter
More informationPrimary and mid-term outcome of sirolimus-eluting stent implantation with angiographic guidance alone
Journal of Cardiology (2008) 51, 18 24 Primary and mid-term outcome of sirolimus-eluting stent implantation with angiographic guidance alone Hajime Fujimoto, Susumu Tao, Tomotaka Dohi, Sachiko Ito, Jun
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More informationBiodegradable Stents An update and work-in
Biodegradable Stents An update and work-in in-progress Department of Cardiology, Hideo Tamai, M.D. Metallic stents... Background induce a varing degree of thrombogenesis eg, subacute thrombosis in complex
More informationstent (stent fracture) clopidogrel in stent restenosis drug eluting stent(des) (overlap) mail:
stent (MD) (MD) clopidogrel (stent fracture) in stent restenosis drug eluting stent() stent post dilation, angulated) (overlap) mail: mehrdadsaravi@gmail.com J Babol Univ Med Sci; 11(5); Dec-Jan 2009-2010
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationFor Personal Use. Copyright HMP 2014
Original Contribution Long-Term Safety and Efficacy of the Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice Israel M. Barbash, MD, Sa ar Minha,
More informationInsights in Thrombosis and In-Stent Restenosis
Clinical Value of OCT Insights in Thrombosis and In-Stent Restenosis Fernando Alfonso MD, PhD, FESC Interventional Cardiology. Cardiovascular Institute. Clinico San Carlos University Hospital. Madrid.
More informationResults of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies
Intracoronary Radiation Therapy Improves the Clinical and Angiographic Outcomes of Diffuse In-Stent Restenotic Lesions Results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationIn-stent Restenosis Diagnostic and Therapeutic Challenges. Kostis Raisakis General Hospital of Athens «G. Gennimatas»
In-stent Restenosis Diagnostic and Therapeutic Challenges Kostis Raisakis General Hospital of Athens «G. Gennimatas» Introduction With POBA, rates of acute and chronic vessel occlusion at 30% to 60%, secondary
More informationRESTENOSIS Facing up to the problem
RESTENOSIS Facing up to the problem Petr Kala University Hospital Brno Czech Republic ESC 2011, Paris Disclosure Scientific Advisory Boards or Education presentations fee Abbott, Boston Scientific, Cordis
More informationEvaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013
Evaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013 Disclosures Consultant- St Jude Medical Boston Scientific Speaker- Volcano Corporation Heart
More informationThe wound healing response after implantation of a drug eluting stent is impaired persistently in the long term
DOI 10.1007/s00380-015-0676-y CASE REPORT The wound healing response after implantation of a drug eluting stent is impaired persistently in the long term Takahisa Nasuno 1 Michiaki Tokura 1 Michiya Kageyama
More informationRestenosis after implantation of sirolimus-eluting stent begins suddenly, shows short term progression, and stops suddenly
Journal of Cardiology (2011) 58, 26 31 a va i la b le at www.sciencedirect.com jo ur nal home page: www.elsevier.com/locate/jjcc Original article Restenosis after implantation of sirolimus-eluting stent
More informationResearch Article Pathological Perspective of Drug-Eluting Stent Thrombosis
Thrombosis Volume 2012, Article ID 219389, 8 pages doi:10.1155/2012/219389 Research Article Pathological Perspective of Drug-Eluting Stent Thrombosis Katsumi Inoue Department of Laboratory Medicine, Kokura
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationCYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
More informationThe Site of Plaque Rupture in Native Coronary Arteries
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.067
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationIntravascular Ultrasound in the Drug-Eluting Stent Era
Journal of the American College of Cardiology Vol. 48, No. 3, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.04.068
More informationUnprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality
Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Shun Watanabe, MD, Tatsuhiko Komiya, MD, Genichi Sakaguchi, MD, PhD, and Takeshi Shimamoto, MD, PhD Department
More informationOptical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents
Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents J-S Kim, 1 I-K Jang, 2 J-S Kim, 1 T H Kim, 1 M Takano, 3 T Kume, 4 N
More informationDrug-eluting stents (DES) have
Hellenic J Cardiol 2011; 52: 1-5 Editorial Coronary Stent Fracture: How Frequent It Is? Does It Matter? Dimitrios Alexopoulos, Ioanna Xanthopoulou Cardiology Department, Patras University Hospital, Greece
More informationAppearance of Lipid-Laden Intima and Neovascularization After Implantation of Bare-Metal Stents
Journal of the American College of Cardiology Vol. 55, No. 1, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.08.032
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationOCT Analysis in Patients With Very Late Stent Thrombosis
JACC: CARDIOVASCULAR IMAGING VOL. 6, NO. 6, 2013 ª 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-878X/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcmg.2013.02.006 OCT
More informationInvasive Coronary Imaging Modalities for Vulnerable Plaque Detection
Invasive Coronary Imaging Modalities for Vulnerable Plaque Detection Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Greyscale IVUS studies have shown Plaque ruptures do not occur randomly
More informationCoronary Heart Disease. Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents
Coronary Heart Disease Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents Neil Sawhney, MD; Jeffrey W. Moses, MD; Martin B. Leon, MD; Richard E. Kuntz, MD; Jeffrey
More informationOCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?
OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationOriginal paper. Introduction. Material and methods. Aim
Original paper Relation between coronary plaque calcium deposits as described by computed tomography coronary angiography and acute results of stent deployment as assessed by intravascular ultrasound Jerzy
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationJACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, 2009 2009 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/09/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.01.012 Incomplete
More informationIn-Stent Restenosis. Can we kill it?
In-Stent Restenosis Can we kill it? However, In-stent Restenosis is the most serious problem (2-25%) More than 15, lesions will need treatment because of in-stent restenosis. Varying Prevalence Rates of
More informationAngiographic long-term results after implantation of the paclitaxel-eluting coronary stent coroflex please : Data under real-world conditions
244 U. Gerk, B. Leithäuser, U. Schäfer, F. Jung, J.-W. Park Applied Cardiopulmonary Pathophysiology 14: 244-249, 2010 Angiographic long-term results after implantation of the paclitaxel-eluting coronary
More informationORIGINAL ARTICLE. Abstract. Introduction. Teruhiko Suzuki 1, Tetsuya Ishikawa 1, Yosuke Nakano 1, Shouryoku Hino 2 and Makoto Mutoh 1
ORIGINAL ARTICLE Propensity Score-matched Lesion-based Comparison of Mid-term Angiographic Outcomes of TAXUS Liberté with Cypher Bx Velocity Stents for De Novo Native Coronary Stenosis and in Patients
More informationINTRODUCTION. Catheterization and Cardiovascular Interventions 82:E871 E878 (2013)
Catheterization and Cardiovascular Interventions 82:E871 E878 (2013) Two-Week Interval Optical Coherence Tomography: Imaging Evidence on Neointimal Coverage Completion After Implantation of the Endeavor
More informationComparison of Optical Coherence Tomographic Assessment between First- and Second-Generation Drug-Eluting Stents
Original Article http://dx.doi.org/10.3349/ymj.2012.53.3.524 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 53(3):524-529, 2012 Comparison of Optical Coherence Tomographic Assessment between First- and
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 6: , 2013
840 Identification of independent risk factors for restenosis following bare metal stent implantation: Role of bare metal stents in the era of drug eluting stents CHANG BUM PARK 1 and HOON KI PARK 2 1
More informationFor Personal Use. Copyright HMP 2013
Case Report J INVASIVE CARDIOL 2013;25(2):E39-E41 A Case With Successful Retrograde Stent Delivery via AC Branch for Tortuous Right Coronary Artery Yoshiki Uehara, MD, PhD, Mitsuyuki Shimizu, MD, PhD,
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More information2yrs 2-6yrs >6yrs BMS 0% 22% 42% DES 29% 41% Nakazawa et al. J Am Coll Cardiol 2011;57:
Pathology of In-stent Neoatherosclerosis in BMS and DES 197 BMS, 103 SES, and 106 PES with implant duration >30 days The incidence of neoatherosclerosis was significantly greater in DES (31%) than BMS
More information